menu search

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...

November 3, 2023, 8:05 pm

Prime medicine reports third quarter 2023 financial results and provides business updates

— Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well...

November 3, 2023, 8:01 pm

New preliminary clinical data on potential of opus aav-based gene therapy for rare inherited retinal disease to be presented at the american academy of ophthalmology annual conference 2023

Data to be presented as part of gene augmentation therapy presentation RALEIGH, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focu...

November 3, 2023, 7:43 pm

Taysha gene therapies: tsha-102's potential is a 'buy'

Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting R...

November 3, 2023, 7:41 pm

Update: korro bio and frequency therapeutics announce closing of merger and private placement of $117 million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...

November 3, 2023, 7:31 pm

Cellectis: end of 2023 data readouts to boost car-t prospects

Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin...

November 3, 2023, 6:57 pm

Actinium pharmaceuticals: the trickle down continues, and i maintain a buy

Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has ...

November 3, 2023, 6:08 pm

Usd/chf price analysis: plummets below 0.9000, golden-cross at risk

USD/CHF drops sharply, signaling potential end to Fed’s rate hikes with investors favoring CHF. Pair�...

November 3, 2023, 5:44 pm

Is it worth it for b2b companies to sponsor leading expos and events?

Sponsoring leading expos and events is a B2B marketing technique that frequently attracts attention and investment. From industry conferences to trade...

November 3, 2023, 5:12 pm

Is real estate industry at risk of being disrupted with zillow ruling?

Realtors have long been seen as the major mediators between buyers and sellers in the real estate sector. However, recent digital advancements, such a...

November 3, 2023, 5:12 pm

Truck stop's suit against berkshire challenges buffett's good guy image

Pilot claims accounting adjustments will potentially shortchange the family that once controlled it....

November 3, 2023, 4:47 pm

Korro bio and frequency therapeutics announce closing of merger and private placement of $117 million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...

November 3, 2023, 4:19 pm

Trust wallet token price forecast: twt soars 11% as traders turn to this turbocharged bitcoin alternative with 20x potential

The Trust Wallet Token price spiked more than 11% over the past 24 hours to trade at $1.24 as of 5:45 am EST as investors began trading the altcoin on...

November 3, 2023, 4:14 pm

Aud/usd: dollar’s strength and poor levels of risk appetite to cap upside potential – rabobank

On balance, we expect USD strength and poor levels of risk appetite to cap upside potential in AUD/USD ...

November 3, 2023, 3:59 pm

Karooooo ltd. increases focus on cartrack division in asia

Karooooo Ltd. reported top-line revenue and operating income growth in its FQ2 2024 financial results. The company offers telematics services and a us...

November 3, 2023, 3:23 pm

Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the...

November 3, 2023, 2:46 pm

Real estate gold: 3 reit stocks with income potential

Real estate investment trusts (REITs) are among the core options for income-based investing. I would go as far as arguing that REITs don't even have t...

November 3, 2023, 1:50 pm

Whoa! don't buy sofi stock until you see this scary statistic.

SoFi Technologies (NASDAQ: SOFI ) stock has strong comeback potential, but be careful. Required federa...

November 3, 2023, 1:42 pm

Apple analysts mixed as weaker guidance weighs on strong margins

Apple Inc (NASDAQ:AAPL)'s fourth-quarter revenue guidance, although below their estimates, is expected to be offset by the company's strong gross marg...

November 3, 2023, 1:13 pm

Mtum: just doesn't live up to the momentum hype

iShares MSCI USA Momentum Factor ETF has not demonstrated much momentum despite its name. The MTUM exchange-traded fund holds 123 individual stocks, w...

November 3, 2023, 1:06 pm


Search within

Pages Search Results: